Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel plus carboplatin versus paclitaxel plus carboplatin for epithelial ovarian cancer
ChiCTR1900024013Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jul 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nab-paclitaxel, paclitaxel and carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Progression-free survival. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
nab-paclitaxelpaclitaxelcarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR1900024013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024013.